Trial Profile

A Phase 2a Study of MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MW 150 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions
Acronyms SKI-AD
Sponsors Neurokine Pharmaceuticals

Most Recent Events

13 Mar 2022 Arm 64 mg MW150 removed. Dose of MW150 minimized from 126mg to 10mg. Concentration of single MW150 capsule changed from 63 to 10 Mg and dosing frequency twice daily cancelled. Exclusion criteria Abnormal liver function tests (ALT or AST) or creatine kinase (CK) upon repeat testing added newly.
13 Mar 2022 Planned End Date changed from 31 Jan 2025 to 30 Nov 2024.
13 Mar 2022 Planned primary completion date changed from 31 Oct 2024 to 31 Aug 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com